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0.0 Abstract 
A rapidly growing body of evidence has shown that chromatin undergoes radical alterations 
as an organism ages, but how these changes relate to aging itself is an open question. It is likely that 
these processes contribute to genomic instability and loss of transcriptional fidelity, which in turn 
drives deleterious age-related phenotypes. Interventions associated with increased healthspan and 
longevity such as reduced insulin / IGF signalling (IIS), inhibition of mTOR and energy depletion 
resulting in SIRT1 / AMPK activation, all have beneficial effects which ameliorate multiple facets of 
age-associated decline. The impact of these interventions on the epigenome is less certain. In this 
review we highlight the potential of these interventions to act directly upon the epigenome and 
promote a youthful chromatin landscape, maintaining genetic and transcriptional memory 
throughout the lifecourse. We propose that this is a fundamental mechanism through which these 
interventions are able to curtail the incidence of age-related disease. By revisiting these well 
characterised interventions, we may be able to identify targetable effectors of chromatin function 
and use this knowledge to enhance healthspan and longevity in human populations through the 
measured application of dietary and small molecule interventions. 
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1.0 Introduction 
Aging is generally defined as the increasing morbidity and mortality of an organism with 
time following the onset of sexual maturity. It is clear that even among multicellular organisms, 
aging is not universal (Gampe et al., 2015). Even in those organisms which do age there is a striking 
variation in longevity even between biologically similar organisms. The origins of this divergence are 
far from certain and are the focus of intense research. Thanks to pioneering work by Kenyon et al it 
is clear that the aging process is plastic, capable of being accelerated or attenuated by a range of 
small molecule dietary and genetic interventions (Kenyon, 2010). A clearer understanding of how 
the aging process can vary so wildly between species and within species, is a prerequisite for full 
application of this knowledge in the pursuit of improving public health.  
1.1  Chromatin Degeneration is a Conserved Feature of Aging  
The greatest barrier to health and longevity in any organism, is the maintenance of 
macromolecules critical to survival. Foremost is the DNA, in complex with histone and non-histone 
proteins collectively termed ‘chromatin’. Chromatin and the mechanisms through which it 
modulates programs of gene expression, referred to as epigenetics, represents an attractive target 
for aging intervention as its down-stream effects are critical to all aspects of health and longevity. 
Disruption of epigenetic programs can therefore impact a huge spectrum of biological functions. By 
this logic it is hoped that through ensuring epigenetic stability, disease-free lifespan can be 
preserved.   
During organismal aging the epigenome undergoes remodelling at both the histone and DNA 
level. Broadly speaking, it is believed that age-related chromatin degeneration is underscored by a 
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loss of heterochromatin at the regions it usually occupies from birth (Imai and Kitano, 1998; 
Villeponteau, 1997). A number of specific chromatin alterations define this process. Loss of 
trimethylation of histone 3 at lysine 9 (H3K9me3) and loss of histone protein 1 (HP1) are common 
features observed in invertebrates and humans. Flies with low HP1 are short lived and reconstitution 
of HP1 levels is sufficient to restore lifespan. Old flies show age-dependent loss of heterochromatin 
markers such as H3K9me2. In humans, lower abundance of both HP1 and H3K9me3 are observed in 
aged human fibroblasts and those suffering from the ‘premature aging syndrome’, Hutchinson-
Gilford progeria (HGPS) (Larson et al., 2012; Scaffidi and Misteli, 2006). In the euchromatic regions of 
the genome, transcriptional dysregulation is accompanied by a loss of  histone 3 lysine 36 
trimethylation (H3K36me3) in invertebrates and yeast (Ni et al., 2012; Sen et al., 2015). On the level 
of DNA methylation, classic studies by Vanyushin et al showed that global cytosine methylation 
decreases globally with age in rats and mice, though more recent evidence of this phenomenon is 
lacking and no such trend has yet been well documented in humans (Vanyushin et al., 1973; Wilson 
et al., 1987). More recently it has been shown that global methylation levels do become more 
variable with age, in a phenomenon described as epigenetic drift (Egger et al., 2004). On a more 
local level, specific gene promoters display an age-dependant increase in methylation at CpG islands, 
associated with transcriptional repression (Waki et al., 2003).  
1.2 Linking Chromatin and Longevity 
Most successful longevity interventions are thought to act through metabolic effectors. 
Interventions such as calorie restriction and rapamycin generally work through inhibition of anabolic 
pathways, perhaps freeing the cell to invest resources into maintenance and stress resistance which 
functions to improve the health and longevity of the cell, tissue and ultimately the whole organism. 
Chromatin represents a hub through which all manner of environmental queues are 
integrated and acted upon.  The extent of cross-talk between the chromatin and the metabolome 
highlights the possibility that chromatin may represent a nexus upon which the proposed trade-off 
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between fecundity and longevity is decided, ultimately influencing the aging trajectories of the 
organism (Gut and Verdin, 2013).  
The re-wiring of the cellular machinery towards a state conducive to longevity relies on 
epigenetic alterations to potentiate down-stream effects on gene expression. The fact that in some 
cases lifespan increases are preserved even after transient application and withdrawal of the 
intervention, or indeed are to one extent or another inherited by subsequent generations by 
epigenetic means, is evidence that epigenetic processes have a functional role in determining the 
rate of age-associated decline (Bitto et al., 2016; Greer et al., 2012).  
Up to now most observations tying epigenetic processes to age-associated decline have 
been correlative. Interventions which impact the aging process will play a formative role in 
determining which chromatin alterations are drivers of aging, as opposed to being a result of aging 
itself. Accelerated aging models are replete with caveats which make them unsuitable for such a 
task, not least of all there is the so far unanswered question of how accurately they phenocopy 
physiological aging. Luckily there is a wealth of data to support the claim that interventions such as 
rapamycin, CR and reduced IIS directly impact true effectors of physiological aging in relatively 
‘natural’ model contexts.  The comparative study of epigenetic perturbations in young vs old 
organisms, with and without longevity-associated interventions, holds promise in delineating which 
epigenetic profiles are causative to the aging process and how they may be attenuated.  
In this review, we will focus upon the direct impact of longevity interventions on two well 
characterised epigenetic read-outs, DNA methylation and histone post-translational modifications. 
We will propose models and mechanisms through which longevity may be preserved by ensuring 
epigenetic stability, as well as highlighting future approaches to apply these findings to enhance 
longevity and delineate epigenetic components of aging mechanisms. The subject of which 
epigenetic changes accompany the aging process will not be discussed further in this publication. 
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This topic has been the subject of a number of excellent reviews, to which the reader is directed in 
the following citations (Booth and Brunet, 2016; Brunet and Berger, 2014; Sen et al., 2016). 
 
 
2.0 Longevity Interventions Impact Age-Associated Epigenetic Aberrations  
Recent studies have focused on identification of age-associated chromatin marks, followed by 
mechanistic investigations usually through genetic modification to amplify or repress the marks in 
question and deduce its effects on known aging mechanisms. It is worth asking how these age-––
associated changes respond in a long lived organism, to observe their effects in a physiological 
model of longevity. One would expect that should this epigenetic damage have a causative role in 
age-related decline, then such damage should be ameliorated or reversed upon application of 
interventions known to attenuate aging. This is indeed the case in a number of instances. (Table.1)  
 
 
 
Table.1 Effects of longevity-associated interventions on age-associated epigenetic alterations. 
 
Organism Mark Change with 
Age 
Phenotype Intervention Result Citation 
Rat DNA methylation Decrease Hypomethylation of specific gene 
loci 
CR Methylation Increase at specific 
gene loci 
(Hass et al., 1993) 
Rat DNA methylation Increase /  
Decrease 
Hyper/Hypomethylation of 
specific gene loci 
CR Attenuation of 
hyper/hypomethylation 
(Kim et al., 2016) 
Human H3K4ac Increase Activation  of P16 CR H3K4ac reduced, suppression of 
P16 
(Li and Tollefsbol, 
2011) 
Human H3K9me3 Decrease Activation  of P16 CR H3K9me3 increased, suppression 
of P16 
(Li and Tollefsbol, 
2011) 
Mouse DNA methylation Decrease Loss of global DNA methylation Reduced growth 
hormone 
Retention of global DNA 
methylation 
(Armstrong et al., 
2014) 
Mouse H3K27me3 Decrease Loss in brain tissue Rapamycin / CR Retention of  H3K27me3 (Gong et al., 2015) 
Mouse H3R2me2 Decrease Loss in brain tissue Rapamycin / CR Retention of  H3R2me2 (Gong et al., 2015) 
Mouse H3K79me3 Decrease Loss in brain tissue Rapamycin / CR Retention of  H3k79me3 (Gong et al., 2015) 
Mouse H4K20me3 Decrease Loss in brain tissue Rapamycin / CR Retention of  H4k20me3 (Gong et al., 2015) 
Yeast  H3 Acetylation Increase Repression of autophagy, 
reduced lifespan 
Spermidine Reduced  H3 acetylation, 
reversed phenotype 
(Eisenberg et al., 
2009) 
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2.1 Diet and Calorie Restriction  
Chromatin and the metabolome are inextricably linked through metabolic cofactors. 
Products of the TCA cycle, glycolysis and -oxidation feed into chromatin modifying enzymes, 
altering their activity and tailoring epigenetic responses to the metabolic phenotype of the cell (Gut 
and Verdin, 2013). Calorie restriction (CR) is probably the best studied and most efficacious of the 
longevity promoting interventions. It is becoming increasingly clear that at least some of its effects 
are tied to epigenetic responses. Over ten years ago Hass et al demonstrated that pancreatic acinar 
cells isolated from CR rats were found to have more methylation present at specific gene loci, 
including well known proto-oncogenes such as Ras, when compared to an ad-libitum fed rats. Ex-
vivo cultures of cells isolated from the CR mice were more resistant to oncogenic transformation. 
This suggested that CR may protect from age-associated decline by promoting maintenance 
methylation at tissue specific repressed genes, preventing spurious activation. This effect appeared 
to be mediated through an increase in the activity of maintenance methyltransferase DNMT1 (Hass 
et al., 1993).  
Related observations around this time showed that age-related DNA methylation of the ER gene CpG 
island correlates with colon neoplasia (Issa et al., 1994). It is now clear that a wide variety of genes 
including tumor suppressors become progressively more methylated with age, more than likely 
contributing to the age-related incidence of diseases such as cancer (So et al., 2006; Waki et al., 
2003). It seems clear that the age-dependent loss of the cell type specific transcriptional regulation 
and genomic integrity afforded to cells by their genome methylation profile is a causative factor in 
age-related decline (Rakyan et al., 2010; Teschendorff and Menon, 2010). That these changes may 
be attenuated by CR is an exciting prospect. 
The more recent application of next-generation sequencing technologies to the question of 
DNA methylation has yielded more promising results. Short term CR in 25-month-old rats seemed to 
attenuate age-dependant methylation alterations in the promoters of genes associated with a large 
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number of age-associated degenerative phenotypes including cancer diabetes and inflammation 
(Kim et al., 2016). However, this study is not without its limitations. In the future studies using 
unbiased whole-genome approaches at a single base-pair resolution, to map changes in the 
methylation landscape in response to age and longevity interventions such as CR, will need to be 
performed. These will reveal the precise magnitude and location of these alterations, as well as their 
potential to be attenuated by interventions.  More work needs to be done to delineate the effects of 
age-related methylation events and investigate whether their reversal by CR is a potential causal 
mechanism in CRs longevity promoting effects.  
CRs effects on the epigenome are not limited to DNA methylation. CR seems to increase the 
activity of histone deacetylases (HDACs), particularly SIRT1, which during CR is localized to age-
associated genes such as p16. This contributes to their repression through H3 hypoacetylation 
particularly at lysine 4, with an associated increase in H3K9me3 at the p16 promoter. This effect 
increases the replicative lifespan of human fibroblasts in vitro (Li and Tollefsbol, 2011).  
The evidence seems to point towards epigenetic reprogramming playing an important role in 
shaping the mammalian cell’s gene expression program toward a state conducive to longer life and 
reduced disease incidence. 
 
2.2 Reduced Growth Hormone Signalling  
The Ames dwarf mouse is a long lived mouse strain, living almost 50% longer than matched 
wild-type mice. They are characterised by a disabling mutation in the Prop1 gene, resulting in 
reduced circulating growth hormone, IGF1, prolactin and thyroid stimulating hormone by virtue of 
an underdeveloped pituitary gland. Similarly to CR mice, Ames dwarf mice have been found to have 
lower protein expression of DNMT1 and higher expression of DNMT3a (Armstrong et al., 2014), 
compared to normal age matched counterparts, suggesting a role for DNA methylation in the Ames 
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dwarf’s maintenance of health and longevity. Global analysis of Ames dwarf DNA methylation 
suggested that the dwarf mouse may maintain DNA methylation better throughout life-course than 
its wildtype counterparts (Armstrong et al., 2014).  
It is worth considering how the DNA methylome of Ames dwarf mice might be linked to its 
metabolome. For example, Ames dwarf mice exhibit elevated glycine N-methyltransferase (GNMT) 
(an enzyme that converts S-adenosyl-methionine (SAM) to S-adenosyl-homocysteine and sarcosine), 
and correspondingly lower levels of SAM, a substrate for DNA methyl transferases (Uthus and 
Brown-Borg, 2003, 2006). Thus, elevated GNMT in Ames dwarf mice might depress the typical age-
associated methylation of CpG islands (Rakyan et al., 2010; Teschendorff and Menon, 2010), perhaps 
contributing to delayed cancer incidence in these mice (Ikeno et al., 2003). 
2.3 Rapamycin and TOR inhibition  
The mammalian target of rapamycin (mTOR) is a master metabolic switch governing 
resource allocation in the cell. Its activation by growth factors and bountiful amino acid availability 
drives cell anabolism through activation of protein translation through signalling to the S6 ribosomal 
protein. It’s repression under conditions of nutrient deprivation or rapamycin treatment, drives 
cellular catabolism, de-repressing autophagic programs and shutting down protein synthesis to free 
up cytosolic resources. mTOR inhibition has been broadly implicated as a longevity assurance 
mechanism (Johnson et al., 2013). Rapamycin, probably the most well characterised means by which 
to inhibit mTOR, has been repeatedly demonstrated to increase lifespan and improve healthspan in 
a range of models (Wilkinson et al., 2012). 
With mTOR occupying such a vital node in metabolic resource allocation, it seems likely that 
these effects would be propagated through epigenetic means. Indeed, recent in-vivo evidence 
suggests that the longevity effects associated with rapamycin persist after transient application and 
withdrawal in middle aged mice, with the length of longevity gain being proportional to the amount 
of time spent on rapamycin. This may suggest that some form of epigenetic reprogramming 
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underlies rapamycin’s longevity enhancing effects and undoubtedly warrants further investigation 
(Bitto et al., 2016). 
Evidence to this effect was observed in a recent study by Gong et al on the brain tissues of 
young and old mice, compared to those treated with longevity interventions including rapamycin. 
Brain tissues of young (6 month) and old (22 month) were isolated and analysed for a number of 
histone modifications. Seven modifications were found to be lost with age. Intriguingly, treatment 
with rapamycin for 3 months from 19 months of age reversed the loss of four of these histone marks 
H3K27me3, H3R2me2, H3K79me3 and H4K20me2 (Gong et al., 2015).  
It is worth noting that Gong observed similar results in life-long CR treated mice, maintained 
at 70% of their recommended calorie intake. That both of these interventions show similar effects 
suggests shared mechanisms are at play, implicating mTOR inhibition in maintenance of histone 
modification profiles with age. 
 
2.4 Histone Deacetylase Inhibitors  
Histone acetylation is thought to be associated with gene activation through cumulative 
negation of histones’ positive charge, causing disruption of the nucleosome on the chromatin and 
ultimately generation of a more open chromatin structure (Zentner and Henikoff, 2013). Altered 
histone acetylation profiles have been associated with aging phenotypes. Most convincingly, 
increased histone acetylation seems to correlate with reduced lifespan in yeast and drosophila. 
Inhibition of lysine acetyl transferases and acetyl-CoA synthases resulted in H3 and H4 
hypoacetylation and increased lifespan (Eisenberg et al., 2014). These observations open up the 
possibility that by ameliorating global age-related histone hyperacetylation using small molecule and 
dietary intervention, we may be able to enhance health and longevity.  
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Spermidine is a naturally occurring polyamine that has been shown to counteract age-
related hyperacetylation of histones related to age-dependant reduction in polyamine metabolism. 
Introduction of spermidine to aged yeast cells reversed hyperacetylation of histone H3 and activated 
gene programs associated with autophagy and cell stress resistance promoting longevity. Depletion 
of polyamines from growth media resulted in hyperacetylation and early death (Eisenberg et al., 
2009).  
The hyperacetylation paradigm runs counter to observations that histone deacetylase 
inhibitors can enhance healthspan and longevity (Krishnan et al., 2011; Zhao et al., 2005). It is 
becoming evident that histone acetylation plays a more nuanced role in gene regulation, with site 
specific changes in histone acetylation playing just as important a role as more global alterations 
(Peleg et al., 2016). It is notable that lifespan increases associated with treatment with histone 
deacetylase inhibitors (HDACi’s) such as trichostatin A (TSA) and butyrate often show more targeted 
gene-specific effects (Tao et al., 2004; Walsh et al., 2015). There may be a role for both approaches 
in maximising health and longevity, whereby global reduction in histone acetylation can be paired 
with gene specific retention of histone acetylation to maintain optimal gene expression programs 
through the life course, by carefully tailored application of nutritional interventions in conjunction 
with HDAC inhibitors. Also worth considering, but beyond the scope of this review, are the diverse 
effects of HDACs and histone acetyltransferases (HATs) on none-histone substrates. 
 
3.0 A Two-Tier Strategy for Targeting Age-related Chromatin Decline  
Global and site-specific chromatin rearrangements accompany aging. Evidence is mounting 
that these changes have profound deleterious effects on cell homeostasis, gene expression 
programs and genomic integrity, which can drive the aging phenotype (López-otín et al., 2013).  
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The literature highlighted here is proof that these alterations can be attenuated through genetic, 
small molecule and dietary means and through doing so, we can ameliorate age-related decline. 
However discrepancies remain. Though we may broadly describe the landscapes of the aging 
epigenome as undergoing ‘heterochromatin loss’ or ‘global hypomethylation’, the true nature of 
age-related chromatin decline can only be satisfactorily described by the product of gross chromatin 
alterations such as these and the myriad of small site-specific often gene-level changes in specific 
histone modifications or DNA methylation events. Both tiers of chromatin organisation must be 
carefully considered and factored in to any future strategy designed to alleviate epigenetic 
dysfunction. We may pragmatically group interventions into two categories based on the scope of 
their action.  
Interventions can be considered ‘globally acting’ if they have the potential to affect the 
availability of a large range of co-factors and may drive non-specific chromatin rearrangements or 
suppress age-associated global changes. Global shifts in metabolic cofactors brought about by 
calorie restriction or macronutrient deprivation may alter cellular availability of enzyme co-factors 
and substrates, such as s-adenosyl-methionine (SAM), acetyl-Co-A (Ac-CoA) and nicotinamide 
adenine dinucleotide (NAD), that will affect all enzymes which rely on these factors, many of which 
being controllers of chromatin methylation and acetylation events. Case in point being that a calorie 
restricted diet seems to attenuate global loss of DNA methylation, potentially by altering the co-
factor abundance of alpha ketoglutarate (αKG) which drives demethylation through TET family 
demethylases, or SAM which is primary methyl donor for a wide range of methyltransferases (Gut 
and Verdin, 2013). Future studies may wish to dissect how these dietary interventions alter 
metabolism and what ramifications these changes have for the epigenome and maintenance of a 
youthful chromatin profile.  
It is the case that alterations which are beneficial on a global scale, may be deleterious at the 
local level for certain genes. Targeting the age-associated trend towards global hypomethylation 
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may beneficially promote genome stability. However an unbiased approach promoting enhanced 
global methylation may inadvertently promote hypermethylation of tumor suppressor genes or 
longevity assurance genes, negating beneficial effects. A similar scenario can be envisioned for 
histone acetylation and methylation. This realization makes it readily apparent that we require more 
knowledge on which chromatin modifying enzymes regulate which genes at a local level and how 
they do so. 
When we reconcile these two tiers, we may rationally design nutritional and 
pharmacological interventions which can buffer against deleterious changes to the global chromatin 
landscape, whilst protecting longevity and health promoting gene circuitry through the rational 
application of more targeted interventions (Figure.1).  
 
 
 
4.0 Concluding remarks   
A small but important literature has demonstrated that longevity interventions attenuate 
age-associated chromatin decline. The result should be cause for excitement and will hopefully 
Fig.1 Visual representation of two-tier approach to ameliorating age-related chromatin decline. Global 
focusing on broad dietary and supplementary interventions to counteract A Histone hyperacetylation 
B DNA hypomethylation. Local focusing on rational design of targeted small molecule combination 
therapies to counteract C Gene-level alterations in histone PTM profiles D Gene-level alterations In 
DNA methylation profiles. 
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inspire more studies to answer our first fundamental questions in this regard. It will be interesting to 
see how much overlap exists between different longevity interventions and the epigenetic 
phenotypes they influence. Future studies may highlight the importance of shared chromatin 
alterations in the pathophysiology of age-related disease and could hint at shared effector pathways 
of known interventions. This is certainly a question worth pursuing, as it could open up new avenues 
by which we can leverage old and new interventions to model the epigenome to a state conducive 
to longevity.   
The literature has demonstrated that through a case-control based study design, we can 
implicate new chromatin marks in age-related epigenetic progression (Fig.2). Gong et al., (2015) 
showed in their study that aged mice show a number of changes to their histone PTM profile 
compared to young mice, some of which were new to age-related cognitive decline, the phenotype 
in question. Further information was gleaned by the fact that some of these marks are reversed 
upon application of longevity interventions. This may help highlight which changes have a key 
mechanistic role in aging. Furthermore, both longevity interventions induced changes in post-
translational histone profile, at sites which showed no change with age. The importance of these 
marks remains to be explored, they may represent passenger changes unrelated to aging, or more 
excitingly these marks may demonstrate their own longevity promoting roles.  
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Pursuit of these questions should be prioritized and will prove highly complementary to the 
correlative studies of age-related chromatin alterations. Then in the near future we may pose the 
most exciting question; by what magnitude can epigenetic interventions be leveraged to stave off 
aging and disease?  
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Highlights 
 
 Ageing is associated with gross alterations to chromatin and epigenetic profiles 
 These epigenetic changes are associated with phenotypes of age related decline 
 Interventions associated with longevity attenuate age related epigenetic change 
 Drug and dietary interventions may ensure longevity through epigenetic stability 
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